AnalystBook Research · Company Intelligence

AtlasClear Holdings, Inc.

ATCHNYSE

Built from AtlasClear Holdings, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

AtlasClear reported $10.9M of revenue and $5.8M of net income, but equity stayed negative and Altman-Z was distress.

The read at a glance✓ Audited against SEC data
  • Business mix — Fintech clearing and banking platformNote
  • Revenue — Revenue was $10.9MNote
  • Profitability — Net income was $5.8MOK
  • Cash — Cash from ops $822KNote
  • Balance sheet — Equity was -$6.8MWatch
  • Insiders — 0 buys / 0 sellsNote
  • Accounting — Altman-Z distressWatch

Business

AtlasClear is building a technology-enabled financial services platform for trading, clearing, settlement, and banking services aimed at financial-services firms.

Leadership changes

From AtlasClear Holdings, Inc.'s own filings, the day they're filed.

  • Steven Carlson · directors · appointmenteff. 2025-09-24
  • Robert D. Keyser · directors · departureeff. 2025-08-07
  • Mark Smith · member of the board of directors · departureeff. 2025-08-04

Latest filings

  • 8-K · Company announcement2026-09-24
  • 10-K · Annual report2026-09-24
  • 8-K · Company announcement2026-09-23
  • 8-K · Company announcement2026-09-16
  • 8-K · Company announcement2026-06-01
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about AtlasClear Holdings, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.